Budeprion Hydrochloride Extended-release Tablets

Indication:May 30, 2008—Teva Pharmaceuticals announced the
introduction and availability of Budeprion XL (bupropion
hydrochloride extended-release tablets USP [XL]),
150 mg. The product is AB-rated and bioequivalent to
Wellbutrin XL tablets. Budeprion XL, an antidepressant
of the aminoketone class, is indicated for the treatment
of major depressive disorder. A major depressive
episode implies the presence of depressed mood or
loss of interest or pleasure. With the addition of this
new strength, Teva now offers the tablets in 150- and
300-mg strengths, in bottle sizes of 30 and 500. All
patients being treated with antidepressants for any
indication should be monitored and observed for
clinical worsening, suicidality, and unusual behavior,
especially during the initial few months of therapy or at
times of dose changes.

Cetirizine Hydrochloride Syrup, 1 mg/mL

Indication:June 19, 2008—Perrigo Co
announced that it received
FDA approval to manufacture and market Cetirizine
Hydrochloride Syrup (Rx only), 1 mg/mL. The product
is indicated for the relief of symptoms associated
with seasonal allergic rhinitis, and it is comparable to
McNeil Consumer Healthcare's Zyrtec Syrup, 1 mg/mL.
This product will add to Perrigo's already existing line
of Cetirizine tablets, Cetirizine D, and Cetirizine OTC
syrup.

Dronabinol

Indication:June 30, 2008—Par Pharmaceutical Companies
announced that it received approval from the FDA for
its Abbreviated New Drug Application for dronabinol,
a generic version of Solvay Pharmaceuticals' Marinol,
a CIII controlled substance. This product is approved
to treat nausea and vomiting associated with cancer
chemotherapy in patients who have failed to respond
adequately to conventional antiemetic treatments.
Dronabinol is contraindicated in any patient who has a
history of hypersensitivity to any cannabinoid, sesame
oil, or any ingredients in dronabinol capsules. Warn
patients not to drive, operate machinery, or engage in
hazardous activity until they establish that they can tolerate
dronabinol and perform such tasks.

Rifampin

Indication:March 31, 2008—
Lannett Co Inc,
a manufacturer
of generic pharmaceuticals,
announced that
it received FDA
approval for its Abbreviated New Drug Application
for Rifampin capsules in 150- and 300-mg strengths.
Rifampin is indicated in the treatment of all forms of
tuberculosis and for the treatment of asymptomatic
carriers of Neisseria meningitidis to eliminate meningococci
from the nasopharynx.